Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies

Aaron W. Pederson, Joseph K. Salama, Daniel J. Haraf, Mary Ellen Witt, Kerstin M. Stenson, Louis Portugal, Tanguy Lim Seiwert, Victoria M. Villaflor, Ezra E.W. Cohen, Everett E. Vokes, Elizabeth A. Blair

Research output: Contribution to journalArticle

Abstract

Background: To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy. Methods. From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles: the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg/m2 on d1), infusional 5-fluorouracil (600 mg/m2/d × 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment. Results: Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n = 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment related toxicity included 46% grade 3 mucositis and 33% grade 3 hematologic toxicity. Six patients required feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none progressed regionally. Five-year locoregional progression free survival was 96%. The 3 and 5 year overall survival was 79% and 59%, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1). Conclusions: Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control for high-risk salivary malignancy patients.

Original languageEnglish (US)
Article number31
JournalHead and Neck Oncology
Volume3
Issue number1
DOIs
StatePublished - Jul 28 2011
Externally publishedYes

Fingerprint

Adjuvant Chemoradiotherapy
Salivary Glands
Neoplasms
Salivary Gland Neoplasms
Esophageal Stenosis
Xerostomia
Mucositis
Hydroxyurea
Parotid Gland
Enteral Nutrition
Chemoradiotherapy
Paclitaxel
Fluorouracil
Disease-Free Survival
Dilatation
Therapeutics
Joints
Radiation
Survival

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Oncology

Cite this

Pederson, A. W., Salama, J. K., Haraf, D. J., Witt, M. E., Stenson, K. M., Portugal, L., ... Blair, E. A. (2011). Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head and Neck Oncology, 3(1), [31]. https://doi.org/10.1186/1758-3284-3-31

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. / Pederson, Aaron W.; Salama, Joseph K.; Haraf, Daniel J.; Witt, Mary Ellen; Stenson, Kerstin M.; Portugal, Louis; Lim Seiwert, Tanguy; Villaflor, Victoria M.; Cohen, Ezra E.W.; Vokes, Everett E.; Blair, Elizabeth A.

In: Head and Neck Oncology, Vol. 3, No. 1, 31, 28.07.2011.

Research output: Contribution to journalArticle

Pederson, AW, Salama, JK, Haraf, DJ, Witt, ME, Stenson, KM, Portugal, L, Lim Seiwert, T, Villaflor, VM, Cohen, EEW, Vokes, EE & Blair, EA 2011, 'Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies', Head and Neck Oncology, vol. 3, no. 1, 31. https://doi.org/10.1186/1758-3284-3-31
Pederson, Aaron W. ; Salama, Joseph K. ; Haraf, Daniel J. ; Witt, Mary Ellen ; Stenson, Kerstin M. ; Portugal, Louis ; Lim Seiwert, Tanguy ; Villaflor, Victoria M. ; Cohen, Ezra E.W. ; Vokes, Everett E. ; Blair, Elizabeth A. / Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. In: Head and Neck Oncology. 2011 ; Vol. 3, No. 1.
@article{ade8d6e585c0495e89fe313df523fc02,
title = "Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies",
abstract = "Background: To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy. Methods. From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles: the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg/m2 on d1), infusional 5-fluorouracil (600 mg/m2/d × 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment. Results: Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n = 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment related toxicity included 46{\%} grade 3 mucositis and 33{\%} grade 3 hematologic toxicity. Six patients required feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none progressed regionally. Five-year locoregional progression free survival was 96{\%}. The 3 and 5 year overall survival was 79{\%} and 59{\%}, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1). Conclusions: Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control for high-risk salivary malignancy patients.",
author = "Pederson, {Aaron W.} and Salama, {Joseph K.} and Haraf, {Daniel J.} and Witt, {Mary Ellen} and Stenson, {Kerstin M.} and Louis Portugal and {Lim Seiwert}, Tanguy and Villaflor, {Victoria M.} and Cohen, {Ezra E.W.} and Vokes, {Everett E.} and Blair, {Elizabeth A.}",
year = "2011",
month = "7",
day = "28",
doi = "10.1186/1758-3284-3-31",
language = "English (US)",
volume = "3",
journal = "Head and Neck Oncology",
issn = "1758-3284",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies

AU - Pederson, Aaron W.

AU - Salama, Joseph K.

AU - Haraf, Daniel J.

AU - Witt, Mary Ellen

AU - Stenson, Kerstin M.

AU - Portugal, Louis

AU - Lim Seiwert, Tanguy

AU - Villaflor, Victoria M.

AU - Cohen, Ezra E.W.

AU - Vokes, Everett E.

AU - Blair, Elizabeth A.

PY - 2011/7/28

Y1 - 2011/7/28

N2 - Background: To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy. Methods. From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles: the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg/m2 on d1), infusional 5-fluorouracil (600 mg/m2/d × 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment. Results: Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n = 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment related toxicity included 46% grade 3 mucositis and 33% grade 3 hematologic toxicity. Six patients required feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none progressed regionally. Five-year locoregional progression free survival was 96%. The 3 and 5 year overall survival was 79% and 59%, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1). Conclusions: Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control for high-risk salivary malignancy patients.

AB - Background: To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy. Methods. From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles: the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg/m2 on d1), infusional 5-fluorouracil (600 mg/m2/d × 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment. Results: Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n = 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment related toxicity included 46% grade 3 mucositis and 33% grade 3 hematologic toxicity. Six patients required feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none progressed regionally. Five-year locoregional progression free survival was 96%. The 3 and 5 year overall survival was 79% and 59%, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1). Conclusions: Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control for high-risk salivary malignancy patients.

UR - http://www.scopus.com/inward/record.url?scp=79960687676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960687676&partnerID=8YFLogxK

U2 - 10.1186/1758-3284-3-31

DO - 10.1186/1758-3284-3-31

M3 - Article

C2 - 21791072

AN - SCOPUS:79960687676

VL - 3

JO - Head and Neck Oncology

JF - Head and Neck Oncology

SN - 1758-3284

IS - 1

M1 - 31

ER -